Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2017 17:00 ET | Source: Zafgen, Inc.

Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected...
October 10, 2017 07:00 ET | Source: Zafgen, Inc.

Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer

BOSTON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected...
September 19, 2017 16:05 ET | Source: Zafgen, Inc.

Zafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference

BOSTON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
September 12, 2017 16:05 ET | Source: Zafgen, Inc.

Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes

BOSTON, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), today announced initiation of ZAF-1061-201, the Company’s Phase 2 clinical trial evaluating ZGN-1061 in patients with type 2...
September 12, 2017 08:00 ET | Source: Zafgen, Inc.

Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes

- Data Demonstrate Dose-Dependent Beneficial Impact of ZGN-1061 on Glucose Tolerance, Body Weight and Cardiometabolic Markers- -Improvements in Glycemic Control Independent of Weight Loss- BOSTON,...
August 08, 2017 16:05 ET | Source: Zafgen, Inc.

Zafgen Reports Second Quarter 2017 Financial Results

-ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes- -Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year- -Ends Quarter with Cash,...
August 02, 2017 16:05 ET | Source: Zafgen, Inc.

Zafgen to Present at the Canaccord Genuity 37th Annual Growth Conference

BOSTON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
August 01, 2017 16:05 ET | Source: Zafgen, Inc.

Zafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results

BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
June 13, 2017 16:05 ET | Source: Zafgen, Inc.

Zafgen to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
June 10, 2017 13:00 ET | Source: Zafgen, Inc.

Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions

-Successful Phase 1 Clinical Trial Garners Late-Breaking ADA Presentation and Supports Advancement to Phase 2 Development- -ZGN-1061 Treatment Improves Glycemic Control and Body Weight in Preclinical...